Cargando…
Prevalence of the CHEK2 R95* germline mutation
BACKGROUND: While germline CHEK2 mutations have been linked to a moderately elevated cancer risk, to date, a limited number of such mutations have been identified. Recently, we reported a germline nonsense mutation (C283T; R95*), introducing an early stop-codon, in two Norwegian patients diagnosed w...
Autores principales: | Knappskog, Stian, Leirvaag, Beryl, Gansmo, Liv B., Romundstad, Pål, Hveem, Kristian, Vatten, Lars, Lønning, Per E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039915/ https://www.ncbi.nlm.nih.gov/pubmed/27708748 http://dx.doi.org/10.1186/s13053-016-0059-0 |
Ejemplares similares
-
MDM4 SNP34091 (rs4245739) and its effect on breast‐, colon‐, lung‐, and prostate cancer risk
por: Gansmo, Liv B., et al.
Publicado: (2015) -
APOBEC3A/B deletion polymorphism and cancer risk
por: Gansmo, Liv B, et al.
Publicado: (2018) -
Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate
por: Gansmo, Liv B., et al.
Publicado: (2016) -
Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer
por: Gansmo, Liv B., et al.
Publicado: (2021) -
MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer
por: Helwa, Reham, et al.
Publicado: (2016)